Ekso Bionics Holdings, Inc. Common Stock Q1 FY2025 Earnings Call

· Earnings call transcript and AI-powered summary

Ekso Bionics Q1 2025 Earnings Summary

Financial Performance (Q1 2025 vs. Q1 2024)

  • Revenue: $3.4 million, down from $3.8 million, primarily due to capital budget constraints at inpatient rehabilitation facilities impacting EksoNR Enterprise Health sales.
  • Gross Profit: $1.8 million (54% margin), compared to $2.0 million (52% margin). Improvement driven by supply chain cost savings and reduced service costs, partially offset by lower Enterprise volumes and distribution mix.
  • Operating Expenses: $5.3 million, essentially flat vs. $5.2 million.
  • Net Loss: $2.9 million ($0.12 per basic/diluted share), improved from $3.4 million ($0.20 per share).
  • Cash Used in Operations: $2.0 million in Q1 2025, down from $3.5 million in Q1 2024.
  • Cash Position: $8.1 million (including restricted cash) as of March 31, 2025, up from $6.5 million at December 31, 2024.

Business & Operational Highlights

  • Legacy Enterprise Health (primarily EksoNR) represented the majority of revenue but experienced softness from macroeconomic-driven capital budget delays at IDNs and IRFs; some federal grant funding also uncertain.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Greetings, and welcome to the Ekso Bionics First Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce to your host, Stephen Kilmer of Investor Relations. Thank you. You may begin. Stephen Kilmer: Thank you, operator, and good afternoon, everyone. Earlier today, Ekso Bionics released financial results for the first quarter ended March 31, 2025. A copy of the press release is available on our website. I would like to point out that management will make statements during this call that include forward-looking statements within the meaning of the federal securities, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial performance or operational expectations or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. Fo

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional